Illustrative image – not actual.Australian healthcare provider Respiri has entered into an agreement with MedAchievers to roll out treatment facilities for asthma, chronic pulmonary disease (COPD) in over 200 Tier-I and II cities across India.
The company intends to make an investment of around Rs 150 crore over the next year through this agreement.
It also plans to ramp up investment over the next three years.
Through this agreement, the company also plans to introduce home-based clinically monitored device Wheezo - a product against asthma and COPD.
The company will set up a manufacturing unit of devices for Respiri in India by early January 2020.
MedAchievers has also inked a joint venture agreement with Health and Patient Services and created Digitilogy Healthtech which will roll out smart ICU facilities with tele-monitoring facilities in early September 2019. Advanced ICU care set up facilities will be created at hospitals in Gurugram under this JV.
The company intends to make an investment of around Rs 150 crore over the next year through this agreement.
It also plans to ramp up investment over the next three years.
Through this agreement, the company also plans to introduce home-based clinically monitored device Wheezo - a product against asthma and COPD.
The company will set up a manufacturing unit of devices for Respiri in India by early January 2020.
MedAchievers has also inked a joint venture agreement with Health and Patient Services and created Digitilogy Healthtech which will roll out smart ICU facilities with tele-monitoring facilities in early September 2019. Advanced ICU care set up facilities will be created at hospitals in Gurugram under this JV.
